The 47 references in paper I. Snegireva I., K. Zatolochina E., M. Darmostukova A., R. Alyautdin N., B. Romanov K., И. Снегирева И., К. Затолочина Э., М. Дармостукова А., Р. Аляутдин Н., Б. Романов К. (2018) “Современные подходы к взаимозаменяемости вакцин // Modern approaches to vaccines interchangeability” / spz:neicon:vedomostincesmp:y:2016:i:4:p:3-8

1
Federal Law of Russian Federation of 22.12.2014 ¹ 429-FZ, «On Amendments to the Federal Law «On Circulation of Medicines» (in Russian).
(check this in PDF content)
2
Borzova M. Interchangeability of biological medicines: fantasy or reality? Remedium 2014; (9): 6–13 (in Russian).
(check this in PDF content)
3
Mironov AN, ed. Guidance on the examination of medicines. V. 4. Moscow: Poligraf-Plus; 2014 (in Russian).
(check this in PDF content)
4
Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. 3rd ed. New York: CRC Press; 2008.
(check this in PDF content)
5
Ozeretskovsky NA, Zatolochina KE, Snegireva II. Proposals for the prevention of adverse events when using immunobiological drugs in the Russian Federation. Bezopasnost i risk farmakoterapii 2015; (2): 25–9 (in Russian).
(check this in PDF content)
6
Borisevich IV, Vorobieva MS, Gayderova LA, Gorbunov MA, Davydov DS, Ignatiev GM et al. Medical immunobiological preparations. Directory. V. 1. Vaccines. Moscow: Gella-print; 2010 (in Russian).
(check this in PDF content)
7
Snegireva II, Zatolochina KE, Darmostukova MA, Khotova TYu, Alyautdin RN, Ozeretskovsky NA. et al. Vaccine Interchangeability. Uspehi sovremennogo estestvoznaniya 2015; (8): 43–7 (in Russian).
(check this in PDF content)
8
Feldman S. Interchangeability of vaccines. Pediatric Infectious Disease Journal 2001; 20(11): 23–9.
(check this in PDF content)
9
Public Health Agency of Canada. Canadian Immunization Guide. PrinciplesofVaccineInterchangeability.Availablefrom: http:// www.phac-aspc.gc.ca/publicat/cig-gci/p01-06-eng.php.
(check this in PDF content)
10
Hepatitis B Vaccine. Position Paper WHO. Wkly Epidemiol Rec. 2009; 84(40): 405–20.
(check this in PDF content)
11
CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60(RR02): 1–60. Available from: http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr6002a1.htm.
(check this in PDF content)
12
CDC. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR 2006; 55(RR16): 1–25. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/ rr5516a1.htm.
(check this in PDF content)
13
Hamborsky J, Kroger A, Wolfe S, eds. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington D. C.: Public Health Foundation; 2015. Available from: http://www.cdc.gov/ vaccines/pubs/pinkbook/hepb.html.
(check this in PDF content)
14
Public Health Agency of Canada. Canadian Immunization Guide.Principles of Vaccine Interchangeability. Available from: http:// www.phacaspc.gc.ca/publicat/cig-gci/p01-06-eng.php.
(check this in PDF content)
15
Salisbury D, Ramsay M, eds. Public Health England. Immunization against Infectious Diseases. Part 2: The diseases, vaccinations and vaccines. 2013. Available from: https://www.gov.uk/government/ uploads/system/uploads/attachment_data/file/263311/Green_Book_ Chapter_18_v2_0.pdf.
(check this in PDF content)
16
Australian Immunization Handbook. 10th ed. Part 4.5. Hepatitis B. 2015. Available from: http://www.immunise.health.gov.au/internet/ immunise/publishing.nsf/Content/Handbook10-home.
(check this in PDF content)
17
Tatochenko VK, Ozeretskovsky NA, Fedorov AM. Immunoprophylaxis 2014 (reference). 12th ed. Moscow: Pediatr; 2014 (in Russian).
(check this in PDF content)
18
Zueva LP, ed. Preventive vaccination in health facilities. St. Petersburg; 2004 (in Russian).
(check this in PDF content)
19
Ozeretskovsky NA, Shalunova NV, Petruchuk EM, Indikova IN. Vaccinoprophylaxis of viral hepatitis B. Epidemiologiya i vaktsinoprofilaktika 2015; (2): 87–95 (in Russian).
(check this in PDF content)
20
State register of medicines. Available from: http:// grls.rosminzdrav.ru/Default.aspx.
(check this in PDF content)
21
Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: WB Saunders; 1999.
(check this in PDF content)
22
Seto D, West DJ, Gilliam RR, Ioli VA, Ferrara DK, Rich B. Antibody responses of healthy neonates to two mixed regimens of hepatitis B vaccine. Pediatr Infect Dis J. 1999; 18(9): 840–2.
(check this in PDF content)
23
Bush LM, Moonsammy GI, Bosciaj A. Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. Vaccine 1991; (9): 807–9.
(check this in PDF content)
24
Kuzin SN. Vaccinoprophylaxis of Hepatitis B: successes and challenges. Vaktsinatsiya 2001; 3(15). Available from: http://medi.ru/ doc/15b1504.htm (in Russian).
(check this in PDF content)
25
Connor BA, Phair J, Sack D, McEniry D, Hornick R, Banerjee D, et al. Randomised, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Clin Infect Dis. 2001; 32(3): 396–401.
(check this in PDF content)
26
Zuckerman JN, Kirkpatrick CT, Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL. U) as a booster following primary immunization with Havrix (1440 EL. U) against hepatitis A. J Travel Med. 1998; 5(1): 18–22.
(check this in PDF content)
27
Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, et al. Randomised, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2000; 19(7/8): 743–50.
(check this in PDF content)
28
Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 1996; 14(10): 982–6.
(check this in PDF content)
29
Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 1997; 15(2): 230–6.
(check this in PDF content)
30
Just M, Berger R, Dreschsler H, Brantschen S, Gluck R. A single vaccination with an inactivated hepatitis A liposome vaccine induces rotective antibodies after only two weeks. Vaccine 1992; 10(11): 737–9.
(check this in PDF content)
31
Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet 1994; 343(8893): 322–4.
(check this in PDF content)
32
Beck B, Hatz C, Loutan L, Steffen R. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminium-adsorbed hepatitis A vaccine. J Travel Med. 2004; 11(4): 201–7.
(check this in PDF content)
33
Sabanin YuV, Kuzin SN. Features of vaccine «Avaxim» according to domestic and foreign literature. Vaktsinatsiya 2005; (2). Available from: http:// medi.ru/doc/15b3903.htm.
(check this in PDF content)
34
Public Health Agency of Canada. National Advisory Committee on Immunization. Canadian Immunization Guide. Principles of Vaccine Interchangeability. 2013. Available from: http://www.phac-aspc.gc.ca/ publicat/cig-gci/.
(check this in PDF content)
35
Medunitsyn NV. Medical immunobiological preparations: a handbook. V. 2. Moscow: Gella-Print; 2010.
(check this in PDF content)
36
Chuprinina RP, Alekseeva IA, Obukhov YuI, Soloviev EA. The effectiveness of immunization pertussis combination vaccines containing whole-cell or acellular pertussis vaccine. Biopreparaty. Profilaktika, diagnostika, lechenie 2014; (4): 4–13 (in Russian).
(check this in PDF content)
37
Babachenko IV. Current concepts of immunogenicity and prophylactic efficacy of acellular DTP vaccines based on complex antigens Pertussis coli. Voprosy sovremennoy pediatrii 2005; 4(5): 35–41 (in Russian).
(check this in PDF content)
38
Fedorov AM, Tatochenko VK. Acellular pertussis vaccine – a new stage in the fight against this infection. Voprosy sovremennoy pediatrii 2005; 4(2): 87–91 (in Russian).
(check this in PDF content)
39
Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 2000; 105(1): e11.
(check this in PDF content)
40
Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100(5): 772–88.
(check this in PDF content)
41
Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR 2002; 51: RR-2.
(check this in PDF content)
42
Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J. 2001; 20: 23–9.
(check this in PDF content)
43
Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907–16.
(check this in PDF content)
44
Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergård T, et al. Mass vaccination of children with pertussis toxoid: Decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis. 2001; 33: 1004–9.
(check this in PDF content)
45
Wirsing von Konig CH, Herden P, Palitzsch D, Schneeweiss B, Bier N. Immunogenicity of acellular pertussis vaccines using two vaccines for primary immunization. Pediatr Infect Dis J. 2000; 19: 757–9.
(check this in PDF content)
46
Greenberg DP, Pickering LK, Senders SD, Bissey JD, Howard RA, Blatter MM, et al. Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. Pediatrics 2002; 109: 666–72.
(check this in PDF content)
47
Tatochenko VK. Combination vaccines. Vaktsinatsiya 2008; (5–6): 3–7 (in Russian). AUTHORS Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation, Petrovsky boulevard 8, bld. 2, Moscow 127051, Russian Federation.
(check this in PDF content)